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Getting Sharper Pictures With Advanced Vascular Imaging?*Jie Sun, MD,y Chun Yuan, PHDyzS ystemic lupus erythematosus (SLE) is aprototypical autoimmune disorder that is char-acterized by the production of various autoanti-
bodies and the presence of chronic systemic
inﬂammation. A clinical manifestation of SLE that
was once neglected but is now gaining increasing
attention is the high prevalence of cardiovascular dis-
ease in these patients. Epidemiological studies have
estimated that the risk of myocardial infarction and
stroke is increased by 5- to 10-fold in SLE patients
compared with the general population (1,2), making it
one of the most potent risk factors for cardiovascular
events. Indeed, a bimodal pattern of mortality has
been described in SLE patients, with coronary death
being the leading cause of long-term mortality several
years after diagnosis (3). Furthermore, it is expected
that the importance of cardiovascular risk assessment
and management will keep growing in the years to
come, as improvements in treatment strategies lead
to overall longer survival rates in SLE patients.
Although coronary vasculitis can be responsible
for a clinical event, atherosclerosis is a much more
common pathological ﬁnding in the coronary ar-
teries in SLE patients, which appear to have accel-
erated progression compared with the decades-long
natural history of atherosclerosis in the general
population (4). A number of case-control studies
have used vascular imaging to compare subclinical
atherosclerosis between SLE patients and age- and
sex-matched control subjects. These studies have
predominantly involved cardiac computed tomogra-
phy to assess coronary artery calciﬁcation and ca-
rotid ultrasound to assess intima-media thickness
and carotid plaques (5–8). Overall, these studies*Editorials published in JACC: Cardiovascular Imaging reﬂect the views
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severe in SLE patients compared with control
subjects, which cannot be explained by traditional
risk factors. Accordingly, the disease itself has be-
en hypothesized as a strong contributing factor for
accelerated atherosclerosis and/or increased plaque
vulnerability.
As previous imaging studies have primarily used
traditional approaches focusing on atherosclerotic
burden, it remains unknown whether differences in
atherosclerotic plaque morphology, tissue composi-
tion, or vulnerable features exist in SLE patients
compared with the general population, as well as
what may be characteristic of atherosclerosis in SLE
patients. This knowledge would help to elucidate
pathogenesis of cardiovascular events in SLE pa-
tients. In a postmortem study of rheumatoid arthritis,
another autoimmune disorder associated with incre-
ased cardiovascular risk, Aubry et al. (9) found that
patients with rheumatoid arthritis actually had a le-
sser extent of atherosclerosis but a higher incidence
of vulnerable plaques and vessel wall inﬂammation
compared with control subjects. In a recent study
using multidetector computed tomography to study
noncalciﬁed coronary plaque, Kiani et al. (10)
reported that noncalciﬁed plaques were associated
with SLE activity measures.
Of note, recent advances in vascular imaging have
allowed a much more detailed characterization of
vessel wall pathologies than traditional imaging
approaches used in previous studies. In particular,
cardiac magnetic resonance (CMR) has demonstrated
its capability to measure plaque tissue composition
and, with the use of contrast agents, assess plaque
inﬂammatory activities (11–13). These advanced
vascular imaging approaches afford new opportu-
nities to clarify atherosclerotic changes that are char-
acteristic of SLE as well as lupus-speciﬁc risk factors.SEE PAGE 762The study by Varma et al. (14) in this issue of iJACC
represents one of the ﬁrst endeavors using advanced
vascular imaging for improved understanding of
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772SLE-associated vessel wall changes in the coronary
artery. Inversion-prepared, contrast-enhanced CMR
was used to examine coronary wall enhancement in
27 SLE patients without cardiac symptoms, who were
then compared with healthy control subjects as well
as patients with established coronary atherosclerosis.
Distinct coronary wall enhancement was noted in SLE
patients and patients with coronary atherosclerosis,
but not in healthy control subjects. Furthermore, the
enhancement is generalized in most SLE patients in
contrast to the “patchy” pattern in patients with
established coronary atherosclerosis.
The SLE group in this study is not as well deﬁned
due to missing relevant clinical information such as
disease duration and medication use, which limited
the interpretation of imaging ﬁndings. The extent of
the difference between SLE patients and control
subjects may represent an overestimation of the true
differences between SLE patients and the general
population because control subjects needed to
demonstrate normal coronary arteries on angiog-
raphy per study protocol. Despite these caveats, the
ﬁndings from contrast-enhanced CMR clearly provide
novel information beyond that of previous studies by
showing generalized coronary wall enhancement in
SLE patients.
Although the imaging ﬁndings add new evidence
to the coronary involvement in SLE patients, their
proper interpretations can be challenging. Arterial
wall enhancement by a gadolinium-based contrast
agent is nonspeciﬁc and can indicate a number of
underlying pathologies such as ﬁbrosis, edema, neo-
vascularization, and inﬂammation, which are associ-
ated with either atherosclerosis or vasculitis. The
diffuse and nonregional pattern of enhancement
favors vasculitis as the underlying disease. Yet
coronary vasculitis is considered a rare condition
compared with coronary atherosclerosis and is
incompatible with the high prevalence of abnor-
mality. Another viable explanation is that early-stage
atherosclerosis that is characterized by endothelial
dysfunction and/or intimal hyperplasia, without
conﬂuent necrotic core or calciﬁcation. The moderate
correlations between coronary wall enhancement
measurements and traditional cardiovascular riskfactors and pulse wave velocity support atheroscle-
rosis as the underlying disease. However, most cor-
relations, with the exception of pulse-wave velocity,
were analyzed using the mixed-study sample, in
which the inclusion of the group with established
coronary atherosclerosis, hence a different pattern of
coronary wall enhancement, limited the value of the
correlations.
In the absence of histological validation, perhaps a
longitudinal study following the subjects over time
will help to clarify some of the questions regarding
the nature of coronary wall enhancement seen in the
SLE group. Will generalized or patchy wall enhance-
ment develop in control subjects? Will the general-
ized coronary wall enhancement in SLE patients
persist, perish, or partition? Will medications matter?
The interscan reproducibility of contrast-enhanced
CMR was not addressed in this study, but will be
key to understanding imaging ﬁndings and estab-
lishing the technique as a novel approach for risk
assessment in SLE patients and others.
Another remaining question is to what extent the
ﬁnding of generalized coronary wall enhancement
indicates increased cardiovascular risk and deﬁnes a
subgroup of SLE patients who warrants further
clinical workup or treatment. Although the imaging
ﬁnding could indicate pathological changes in
the coronary artery, the very high prevalence of
enhancement in the SLE group suggests that this
phenomenon alone may not be sufﬁcient for this
purpose. Further understanding of the natural history
of coronary wall enhancement and its associations
with other imaging ﬁndings are needed.
With more questions raised than answered, the
pioneering work by Varma et al. (14) calls for
further collaborative efforts between cardiologists,
rheumatologists, and radiologists to address these
unique challenges in the contemporary management
of SLE patients.
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